ArticleOncoimmunology2016
Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4Journal of virology · 2025Article
- Review
- Signal-transducing innate receptors in tumor immunity.Cancer science · 2021Review
- PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.Nature communications · 2021Article
- Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.Frontiers in cellular and infection microbiology · 2021Review
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities.Frontiers in microbiology · 2019Review
- Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.Cell death & disease · 2018Article
- Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, we introduce a double-stranded RNA mimic that is chemically synthesized to exclusively stimulate toll-like receptor 3 (TLR3). This function-defined TLR3 ligand, named ARNAX, acts as an adjuvant to induce antitumor CTL and NK without significant cytokinemia in mice, and thus superior to polyI:C for therapeutic vaccine immunotherapy against tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.